Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. It operates in a single reportable business segment, which is Pharmaceuticals. The Company’s products include Arachitol Nano, Digeraft, Influvac, Colospa, Duphalac, Librax, Creon, Duphaston, Prothiaden, Cremaffin, Duvadilan, Thyronorm, Cremaffin Plus, Ganaton, Udiliv, Digene, Heptral, Vertin, Zolfresh, Citrosoda UTI, Digene Insta On The Go, Digeraft tablet, Duphaston OD, Pneumoshield 14, Prothiaden Neu, Vonefi, Levesam, and LOBATE M Skin Cream, among others. The Company sells its products through independent distributors primarily within India.As of 25 May 2026, Abbott India share price is ₹27,735.00. The stock opened at ₹27,885.00, compared to its previous close of ₹27,830.00. During today's trading session, Abbott India share price moved in the range of ₹27,400.00 to ₹27,965.00, with an average price of ₹27,682.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹27,400.00 and a high of ₹27,965.00. On the performance front, Abbott India share price has declined by 8.28% over the last six months and is down 10.03% on a year-on-year basis.
The market capitalization of Abbott India is ₹465 Crs, with a P/E ratio of 38.1 and a dividend yield of 1.71%.